Search

Your search keyword '"Krisna, Sai Sakktee"' showing total 32 results
Start Over Author "Krisna, Sai Sakktee"
32 results on '"Krisna, Sai Sakktee"'

1. Analysis of lipid uptake, storage, and fatty acid oxidation by group 2 innate lymphoid cells.

Author

Roy-Dorval, Audrey, Deagle, Rebecca C., Roth, Frederik, Raybaud, Mathilde, Ismailova, Nailya, Krisna, Sai Sakktee, Aboud, Damon G. K., Stegen, Camille, Leconte, Julien, Berberi, Gabriel, Esomojumi, Ademola, and Fritz, Jörg H.

Subjects
FATTY acid oxidation, INNATE lymphoid cells, FATTY acid analysis, LIPID metabolism, IMMUNE response
Abstract

Group 2 Innate Lymphoid Cells (ILC2) are critical drivers of both innate and adaptive type 2 immune responses, known to orchestrate processes involved in tissue restoration and wound healing. In addition, ILC2 have been implicated in chronic inflammatory barrier disorders in type 2 immunopathologies such as allergic rhinitis and asthma. ILC2 in the context of allergen-driven airway inflammation have recently been shown to influence local and systemic metabolism, as well as being rich in lipid-storing organelles called lipid droplets. However, mechanisms of ILC2 lipid anabolism and catabolism remain largely unknown and the impact of these metabolic processes in regulating ILC2 phenotypes and effector functions has not been extensively characterized. ILC2 phenotypes and effector functions are shaped by their metabolic status, and determining the metabolic requirements of ILC2 is critical in understanding their role in type 2 immune responses and their associated pathophysiology. We detail here a novel experimental method of implementing flow cytometry for large scale analysis of fatty acid uptake, storage of neutral lipids, and fatty acid oxidation in primary murine ILC2 with complementary morphological analysis of lipid storage using confocal microscopy. By combining flow cytometry and confocal microscopy, we can identify the metabolic lipid requirements for ILC2 functions as well as characterize the phenotype of lipid storage in ILC2. Linking lipid metabolism pathways to ILC2 phenotypes and effector functions is critical for the assessment of novel pharmaceutical strategies to regulate ILC2 functions in type 2 immunopathologies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Data from Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer

Author

Prabhu, Sathyen A., primary, Moussa, Omar, primary, Gonçalves, Christophe, primary, LaPierre, Judith H., primary, Chou, Hsiang, primary, Huang, Fan, primary, Richard, Vincent R., primary, Ferruzo, Pault Y. M., primary, Guettler, Elizabeth M., primary, Soria-Bretones, Isabel, primary, Kirby, Laura, primary, Gagnon, Natascha, primary, Su, Jie, primary, Silvester, Jennifer, primary, Krisna, Sai Sakktee, primary, Rose, April A. N., primary, Sheppard, Karen E., primary, Cescon, David W., primary, Mallette, Frédérick A., primary, Zahedi, Rene P., primary, Borchers, Christoph H., primary, del Rincon, Sonia V., primary, and Miller, Wilson H., primary

Published
2023
Full Text
View/download PDF

3. Supplementary Figure 1 from Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer

Author

Prabhu, Sathyen A., primary, Moussa, Omar, primary, Gonçalves, Christophe, primary, LaPierre, Judith H., primary, Chou, Hsiang, primary, Huang, Fan, primary, Richard, Vincent R., primary, Ferruzo, Pault Y. M., primary, Guettler, Elizabeth M., primary, Soria-Bretones, Isabel, primary, Kirby, Laura, primary, Gagnon, Natascha, primary, Su, Jie, primary, Silvester, Jennifer, primary, Krisna, Sai Sakktee, primary, Rose, April A. N., primary, Sheppard, Karen E., primary, Cescon, David W., primary, Mallette, Frédérick A., primary, Zahedi, Rene P., primary, Borchers, Christoph H., primary, del Rincon, Sonia V., primary, and Miller, Wilson H., primary

Published
2023
Full Text
View/download PDF

4. Supplementary Data from Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer

Author

Prabhu, Sathyen A., primary, Moussa, Omar, primary, Gonçalves, Christophe, primary, LaPierre, Judith H., primary, Chou, Hsiang, primary, Huang, Fan, primary, Richard, Vincent R., primary, Ferruzo, Pault Y. M., primary, Guettler, Elizabeth M., primary, Soria-Bretones, Isabel, primary, Kirby, Laura, primary, Gagnon, Natascha, primary, Su, Jie, primary, Silvester, Jennifer, primary, Krisna, Sai Sakktee, primary, Rose, April A. N., primary, Sheppard, Karen E., primary, Cescon, David W., primary, Mallette, Frédérick A., primary, Zahedi, Rene P., primary, Borchers, Christoph H., primary, del Rincon, Sonia V., primary, and Miller, Wilson H., primary

Published
2023
Full Text
View/download PDF

5. Supplementary Figure 2 from Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer

Author

Prabhu, Sathyen A., primary, Moussa, Omar, primary, Gonçalves, Christophe, primary, LaPierre, Judith H., primary, Chou, Hsiang, primary, Huang, Fan, primary, Richard, Vincent R., primary, Ferruzo, Pault Y. M., primary, Guettler, Elizabeth M., primary, Soria-Bretones, Isabel, primary, Kirby, Laura, primary, Gagnon, Natascha, primary, Su, Jie, primary, Silvester, Jennifer, primary, Krisna, Sai Sakktee, primary, Rose, April A. N., primary, Sheppard, Karen E., primary, Cescon, David W., primary, Mallette, Frédérick A., primary, Zahedi, Rene P., primary, Borchers, Christoph H., primary, del Rincon, Sonia V., primary, and Miller, Wilson H., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Methods and Tables from Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer

Author

Prabhu, Sathyen A., primary, Moussa, Omar, primary, Gonçalves, Christophe, primary, LaPierre, Judith H., primary, Chou, Hsiang, primary, Huang, Fan, primary, Richard, Vincent R., primary, Ferruzo, Pault Y. M., primary, Guettler, Elizabeth M., primary, Soria-Bretones, Isabel, primary, Kirby, Laura, primary, Gagnon, Natascha, primary, Su, Jie, primary, Silvester, Jennifer, primary, Krisna, Sai Sakktee, primary, Rose, April A. N., primary, Sheppard, Karen E., primary, Cescon, David W., primary, Mallette, Frédérick A., primary, Zahedi, Rene P., primary, Borchers, Christoph H., primary, del Rincon, Sonia V., primary, and Miller, Wilson H., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 3 from Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer

Author

Prabhu, Sathyen A., primary, Moussa, Omar, primary, Gonçalves, Christophe, primary, LaPierre, Judith H., primary, Chou, Hsiang, primary, Huang, Fan, primary, Richard, Vincent R., primary, Ferruzo, Pault Y. M., primary, Guettler, Elizabeth M., primary, Soria-Bretones, Isabel, primary, Kirby, Laura, primary, Gagnon, Natascha, primary, Su, Jie, primary, Silvester, Jennifer, primary, Krisna, Sai Sakktee, primary, Rose, April A. N., primary, Sheppard, Karen E., primary, Cescon, David W., primary, Mallette, Frédérick A., primary, Zahedi, Rene P., primary, Borchers, Christoph H., primary, del Rincon, Sonia V., primary, and Miller, Wilson H., primary

Published
2023
Full Text
View/download PDF

8. Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer

Author

Prabhu, Sathyen A., primary, Moussa, Omar, additional, Gonçalves, Christophe, additional, LaPierre, Judith H., additional, Chou, Hsiang, additional, Huang, Fan, additional, Richard, Vincent R., additional, Ferruzo, Pault Y. M., additional, Guettler, Elizabeth M., additional, Soria-Bretones, Isabel, additional, Kirby, Laura, additional, Gagnon, Natascha, additional, Su, Jie, additional, Silvester, Jennifer, additional, Krisna, Sai Sakktee, additional, Rose, April A. N., additional, Sheppard, Karen E., additional, Cescon, David W., additional, Mallette, Frédérick A., additional, Zahedi, Rene P., additional, Borchers, Christoph H., additional, del Rincon, Sonia V., additional, and Miller, Wilson H., additional

Published
2022
Full Text
View/download PDF

13. The MNK1/2–eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer

Author

Guo, Qianyu, primary, Bartish, Margarita, additional, Gonçalves, Christophe, additional, Huang, Fan, additional, Smith-Voudouris, Julian, additional, Krisna, Sai Sakktee, additional, Preston, Samuel E.J., additional, Emond, Audrey, additional, Li, Vivian Z., additional, Duerr, Claudia U., additional, Gui, Yirui, additional, Cleret-Buhot, Aurélie, additional, Thebault, Pamela, additional, Lefrère, Hanne, additional, Lenaerts, Liesbeth, additional, Plourde, Dany, additional, Su, Jie, additional, Mindt, Barbara C., additional, Hewgill, Shannon A., additional, Cotechini, Tiziana, additional, Hindmarch, Charles C.T., additional, Yang, William, additional, Khoury, Elie, additional, Zhan, Yao, additional, Narykina, Valeria, additional, Wei, Yuhong, additional, Floris, Giuseppe, additional, Basik, Mark, additional, Amant, Frédéric, additional, Quail, Daniela F., additional, Lapointe, Réjean, additional, Fritz, Jörg H., additional, del Rincon, Sonia V., additional, and Miller, Wilson H., additional

Published
2021
Full Text
View/download PDF

15. The pleiotropic effects of the MNK1/2-eIF4E axis support immune suppression and metastasis in a model of postpartum breast cancer

Author

Guo, Qianyu, primary, Bartish, Margarita, additional, Goncalves, Christophe, additional, Huang, Fan, additional, Krisna, Sai Sakktee, additional, Preston, Samuel E. J., additional, Emond, Audrey, additional, Li, Vivian Zihui, additional, Duerr, Claudia U., additional, Gui, Yirui, additional, Cleret-Buhot, Aurélie, additional, Thébault, Paméla, additional, Lefrère, Hanne, additional, Lenaerts, Liesbeth, additional, Plourde, Dany, additional, Su, Jie, additional, Mindt, Barbara C., additional, Hewgill, Shannon, additional, Cotechini, Tiziana, additional, Hindmarch, Charles, additional, Yang, William, additional, Khoury, Elie, additional, Zhan, Yao, additional, Narykina, Valeria, additional, Wei, Yuhong, additional, Floris, Giuseppe, additional, Basik, Mark, additional, Amant, Frédéric, additional, Quail, Daniela F., additional, Lapointe, Réjean, additional, Fritz, Jörg H., additional, del Rincón, Sonia V., additional, and Miller, Wilson H., additional

Published
2020
Full Text
View/download PDF

19. Group 2 Innate Lymphoid Cells are Increased in Patients with Moderate-To-Severe Atopic Dermatitis

Author

Krisna, Sai Sakktee, Sehmi, Roma, and Medical Sciences

Subjects
Atopic Dermatitis, Innate Lymphoid Cells, Group 2 Innate Lymphoid Cells, ILC2
Abstract

Introduction: Atopic dermatitis (AD) is characterized by chronic pruritic relapsing eczematous lesions of the skin. Eosinophilic inflammation in AD is driven by activation of type 2 inflammatory cells including CD4+ T cells and type 2 innate lymphoid cells (ILC2s). We have shown that type 2 cytokines, namely interleukin (IL)-5 and IL-13, stimulate migration and terminal differentiation of eosinophil progenitor cells (EoPs). We propose that these cytokines are important drivers of tissue eosinophilia in AD lesional skin. This study aimed to quantify, by flow cytometry, cells that produce type 2 cytokines in lesional skin compared to peripheral blood from moderate-severe AD patients. Methods: In a cross-sectional study of patients with moderate-to-severe AD (n=16), type 2 inflammatory cells were enumerated in blood and cells extracted from excised skin biopsies. By flow cytometry, live, singlet CD45+cells were identified as ILC2 (lin-CD127+CD294+), EoP (CD34+125+), and CD4+ T cells (Lin+CD3+CD4+). Intracellular expression of type 2 cytokines (IL-5 and IL-13) were evaluated in each cell population. In addition, we developed a protocol to enumerate ILC2s by fluorescence immune-histochemistry in lesional versus non-lesional skin samples and skin biopsies taken 24h post-intradermal challenge with allergen versus diluent. Data are expressed as median (interquartile range [IQR]) unless otherwise stated. Cross compartmental comparisons were made using the Wilcoxon rank-sum test and where applicable, correlational analyses were performed using a Spearman’s rank-correlational test. Results: There was a significantly higher number of total ILC2s in lesional skin compared to blood from AD subjects (556 [99 – 5501] vs 235 [67 – 569] cells/mL, p=0.03). Similarly, IL-5+, IL-13+ ILC2s, were significantly greater in skin compared to blood (6 [1 – 666] vs 1 [1 – 19] cells/mL, p=0.03; 28 [1 – 1357] vs 1 [1 – 7] cells/mL, p=0.01, respectively). We found higher numbers of total and type 2 cytokine positive EoP in lesional skin biopsies from AD patients compared to blood (Total EoP: 815 [285 – 2794] vs 112 [46 – 247] cells/mL, p

Published
2018

22. Abstract 2109: Clonal heterogeneity of EGFR TKI-resistant NSCLC revealed through single-cell dilutional cloning and high-throughput functional screens

Author

Lau, Dawn Pingxi, primary, Rikka, Shivaji, additional, Leong, Hui Sun, additional, Tan, Gek San, additional, Christodoulou, Eleni G, additional, Krisna, Sai Sakktee, additional, Toh, Shen Yon, additional, Kwang, Xue Lin, additional, Chong, Fui Teen, additional, Liew, Audrey Ann, additional, Lim, Tony Kiat Hon, additional, Ramanuj, DasGupta, additional, Iyer, N Gopalakrishna, additional, and Tan, Daniel Shao-Weng, additional

Published
2016
Full Text
View/download PDF

24. Mutational Aberrations Detected in Mucinous Epithelial Ovarian Cancer of Asian Women.

Author

Wen Yee Chay, Li Lian Kwok, Wen Ning Tiong, Krisna, Sai Sakktee, Kiat Hon Lim, Iyer, N. Gopalkrishna, Liang Kee Goh, and Shao-Weng Tan, Daniel

Abstract

Background: Mucinous epithelial ovarian cancers (mEOCs) respond poorly to conventional chemotherapy and have a poor prognosis in advanced stages. The genomic landscape for mEOC in the Asian settings is ill defined. We seek to identify various mutational aberrations present in mEOC and correlate them with clinical outcomes. Methods: A total of 199 cases of mEOC were identified from a prospectively maintained gynecologic oncology tumor database. DNA was extracted and analyzed for KRAS mutations by using Sanger sequencing. Further MassArray sequencing was performed on 45 samples. Clinicopathologic correlation was performed with the results obtained. Findings: KRAS mutation status was evaluable in 124 cases. Fifty-five percent (68/124) were KRAS negative, whereas 45% (56/124) harbored a KRAS mutation, lower than that in Western populations. Successful ascertainment of both KRAS and HER2 statuses by Sanger sequencing occurred for 105 cases. The proportion of the double-positive subtype (HER2+ and KRAS positive) was 8% (8/105); double-negative subtype (HER2j and KRAS negative), 34% (36/105); and cases with mutation in either KRAS or HER2, 58% (61/105). The KRAS mutation rate was 44%, 50%, and 29% among Chinese, Indians, and Malays, respectively. There was no significant difference in overall survival (P = 0.952) or progression-free survival (P = 0.635) between KRAS-positive and KRAS-negative patients. Similar results were observed for progression-free survival (P = 0.206) and overall survival (P = 0.440) when outcomes were examined between the 4 groups based on KRAS and HER2 mutation. Patients in the doublenegative mutation subgroup had higher risk for death/progression compared with patients in the other 3 mutation subgroups. FurtherMassARRAYmultiplexed profilingwas performed in patients with sufficientDNAmaterial (n = 45) and yielded KRAS mutations (n = 16), PDGFRAmutations (n = 3), PIK3CA (n = 1) and KIT (n = 1), and HRAS, FGFR, MET, and NRAS (n = 1 each). Conclusions: Our study provides further knowledge about the mutational aberrations in mEOC in Asian populations. Neither the presence of KRAS mutation nor their correlation with HER2 mutations influenced outcomes. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

25. Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells

Author

Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science, Han, Jongyoon, Khoo, Bee Luan, Warkiani, Majid Ebrahimi, Tan, Daniel Shao-Weng, Bhagat, Ali Asgar S., Irwin, Darryl, Lau, Dawn Pingxi, Lim, Alvin S. T., Lim, Kiat Hon, Krisna, Sai Sakktee, Lim, Wan-Teck, Yap, Yoon Sim, Lee, Soo Chin, Soo, Ross A., Lim, Chwee Teck, Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science, Han, Jongyoon, Khoo, Bee Luan, Warkiani, Majid Ebrahimi, Tan, Daniel Shao-Weng, Bhagat, Ali Asgar S., Irwin, Darryl, Lau, Dawn Pingxi, Lim, Alvin S. T., Lim, Kiat Hon, Krisna, Sai Sakktee, Lim, Wan-Teck, Yap, Yoon Sim, Lee, Soo Chin, Soo, Ross A., and Lim, Chwee Teck

Abstract

Background: Circulating tumor cells (CTCs) are cancer cells that can be isolated via liquid biopsy from blood and can be phenotypically and genetically characterized to provide critical information for guiding cancer treatment. Current analysis of CTCs is hindered by the throughput, selectivity and specificity of devices or assays used in CTC detection and isolation. Methodology/Principal Findings: Here, we enriched and characterized putative CTCs from blood samples of patients with both advanced stage metastatic breast and lung cancers using a novel multiplexed spiral microfluidic chip. This system detected putative CTCs under high sensitivity (100%, n = 56) (Breast cancer samples: 12–1275 CTCs/ml; Lung cancer samples: 10–1535 CTCs/ml) rapidly from clinically relevant blood volumes (7.5 ml under 5 min). Blood samples were completely separated into plasma, CTCs and PBMCs components and each fraction were characterized with immunophenotyping (Pan-cytokeratin/CD45, CD44/CD24, EpCAM), fluorescence in-situ hybridization (FISH) (EML4-ALK) or targeted somatic mutation analysis. We used an ultra-sensitive mass spectrometry based system to highlight the presence of an EGFR-activating mutation in both isolated CTCs and plasma cell-free DNA (cf-DNA), and demonstrate concordance with the original tumor-biopsy samples. Conclusions/Significance: We have clinically validated our multiplexed microfluidic chip for the ultra high-throughput, low-cost and label-free enrichment of CTCs. Retrieved cells were unlabeled and viable, enabling potential propagation and real-time downstream analysis using next generation sequencing (NGS) or proteomic analysis., Singapore-MIT Alliance for Research and Technology

Published
2014

27. Interactions between clinical factors, p16, and cyclin-D1 expression and survival outcomes in oropharyngeal and hypopharyngeal squamous cell carcinoma

Author

Ang, Siok-Hoon, primary, Haaland, Benjamin, additional, Acharyya, Sanchalika, additional, Thu, Minn M. M., additional, Krisna, Sai-Sakktee, additional, Hwang, Siok-Gek, additional, Tan, Puay-Hoon, additional, Ng, Quan-Sing, additional, Tan, Daniel S. W., additional, Tai, Wai-Meng, additional, Tan, Eng-Huat, additional, Lim, Wan-Teck, additional, and Ang, Mei-Kim, additional

Published
2014
Full Text
View/download PDF

28. Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells

Author

Khoo, Bee Luan, primary, Warkiani, Majid Ebrahimi, additional, Tan, Daniel Shao-Weng, additional, Bhagat, Ali Asgar S., additional, Irwin, Darryl, additional, Lau, Dawn Pingxi, additional, Lim, Alvin S. T., additional, Lim, Kiat Hon, additional, Krisna, Sai Sakktee, additional, Lim, Wan-Teck, additional, Yap, Yoon Sim, additional, Lee, Soo Chin, additional, Soo, Ross A., additional, Han, Jongyoon, additional, and Lim, Chwee Teck, additional

Published
2014
Full Text
View/download PDF

29. Bosutinib inhibits migration and invasion via ack1 in kras mutant non-small cell lung cancer

Author

Tan, Daniel SW, primary, Haaland, Benjamin, additional, Gan, Jia Min, additional, Tham, Su Chin, additional, Sinha, Indrajit, additional, Tan, Eng Huat, additional, Lim, Kiat Hon, additional, Takano, Angela, additional, Krisna, Sai Sakktee, additional, Thu, Minn Minn Myint, additional, Liew, Hoe Peng, additional, Ullrich, Axel, additional, Lim, Wan-Teck, additional, and Chua, Boon Tin, additional

Published
2014
Full Text
View/download PDF

32. Inhibition of the MNK1/2-eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer.

Author

Prabhu SA, Moussa O, Gonçalves C, LaPierre JH, Chou H, Huang F, Richard VR, Ferruzo PYM, Guettler EM, Soria-Bretones I, Kirby L, Gagnon N, Su J, Silvester J, Krisna SS, Rose AAN, Sheppard KE, Cescon DW, Mallette FA, Zahedi RP, Borchers CH, Del Rincon SV, and Miller WH

Subjects
Animals, Mice, Eukaryotic Initiation Factor-4E, Piperazines pharmacology, Pyridines pharmacology, Antineoplastic Agents pharmacology, Melanoma drug therapy, Breast Neoplasms drug therapy, Protein Kinase Inhibitors pharmacology
Abstract

Aberrant cell-cycle progression is characteristic of melanoma, and CDK4/6 inhibitors, such as palbociclib, are currently being tested for efficacy in this disease. Despite the promising nature of CDK4/6 inhibitors, their use as single agents in melanoma has shown limited clinical benefit. Herein, we discovered that treatment of tumor cells with palbociclib induces the phosphorylation of the mRNA translation initiation factor eIF4E. When phosphorylated, eIF4E specifically engenders the translation of mRNAs that code for proteins involved in cell survival. We hypothesized that cancer cells treated with palbociclib use upregulated phosphorylated eIF4E (phospho-eIF4E) to escape the antitumor benefits of this drug. Indeed, we found that pharmacologic or genetic disruption of MNK1/2 activity, the only known kinases for eIF4E, enhanced the ability of palbociclib to decrease clonogenic outgrowth. Moreover, a quantitative proteomics analysis of melanoma cells treated with combined MNK1/2 and CDK4/6 inhibitors showed downregulation of proteins with critical roles in cell-cycle progression and mitosis, including AURKB, TPX2, and survivin. We also observed that palbociclib-resistant breast cancer cells have higher basal levels of phospho-eIF4E, and that treatment with MNK1/2 inhibitors sensitized these palbociclib-resistant cells to CDK4/6 inhibition. In vivo we demonstrate that the combination of MNK1/2 and CDK4/6 inhibition significantly increases the overall survival of mice compared with either monotherapy. Overall, our data support MNK1/2 inhibitors as promising drugs to potentiate the antineoplastic effects of palbociclib and overcome therapy-resistant disease., (©2022 American Association for Cancer Research.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results